JPRN-UMIN000000817已完成2 期
Phase II study of TS-1 for patients with advanced non-small cell lung cancer treated with prior chemotherapy. - Phase II study of TS-1 for patients with advanced non-small cell lung cancer treated with prior chemotherapy.
agasaki Thoracic Oncology Group0 个研究点目标入组 32 人开始时间: 2007年9月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Massive pleural effusion 2) Massivepericardial effusion 3) Interstitial pneumonitis 4) Uncontrolled brain metastasis 5) Active infection
研究者
相似试验
已完成
2 期
Phase II Study of TS-1 with Patient-Reported Outcome(PRO) Evaluation in Elderly Patients with Advanced NSCLCon-small cell lung cancerJPRN-UMIN000002035Department of Respiratory Medicine & Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School40
已完成
2 期
Phase II study of TS-1 in elderly patients with unresectable non-small cell lung canceron-small cell lung cancerJPRN-UMIN000000793agasaki Thoracic Oncology Group32
进行中（未招募）
1 期
Ipilimumab, nivolumab and tocilizumab in pretreated patients with advanced pancreatic cancer.Pretreated patients with advanced pancreatic cancer.MedDRA version: 21.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10033607Term: Pancreatic cancer recurrentSystem Organ Class: 100000004864EUCTR2019-004438-40-DKDepartment of Oncology, Herlev & Gentofte Hospital30
已完成
2 期
Phase II study of TAS-102 in patients with advanced gastric cancer after progression on 1 or 2 prior systemic chemotherapyadvanced gastric cancerJPRN-UMIN000007421ational Cancer Center Hospital East28
未知
2 期
An early phase 2 study of NST-141 in patients with atopic dermatitisPruritus associated with atopic dermatitisJPRN-jRCT2080221375TAIHO PHARMACEUTICAL CO.,LTD, NIPPON SHINYAKU CO.,LTD120